Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. Show more
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States
Start AI Chat
Market Cap
1.13B
52 Wk Range
$1.04 - $2.58
Previous Close
$1.77
Open
$1.77
Volume
23,831,466
Day Range
$1.77 - $1.97
Enterprise Value
614.3M
Cash
380.5M
Avg Qtr Burn
-13.58M
Insider Ownership
0.11%
Institutional Own.
76.44%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome | Approved Quarterly sales | |
Imetelstat (GRN163L) Details Myelofibrosis | Phase 3 Interim Update | |
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 2 Update | |
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis | Phase 1b Update |
